DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1939)

Rheumatoid Arthritis | Unmet Need | Detailed, Expanded Analysis: TNF-alpha Refractory Rheumatoid Arthritis (US & EU )

Rheumatoid Arthritis | Unmet Need | Detailed, Expanded Analysis: TNF-alpha Refractory Rheumatoid Arthritis (US & EU )

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

MARKET OUTLOOK

Rheumatoid arthritis (RA) patients refractory to one or more TNF-α inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol-Myers Squibb’s Orencia, Roche’s Actemra / RoActemra, Roche’s Rituxan / MabThera). The recent launch of Pfizer’s Xeljanz in Europe and Eli Lilly / Incyte’s Olumiant in both the United States and Europe provides physicians additional treatment options with a convenient oral route of administration. The launch of an additional IL-6 inhibitor, Regeneron / Sanofi’s Kevzara, has further expanded the treatment armamentarium. Although the RA market offers multiple efficacious and relatively safe agents, patients refractory to TNF-α inhibitors have limited options, even with the recent entry of these newer agents; therefore, unmet need still exists for the TNFi-refractory RA subpopulation.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for TNFi-refractory RA?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for TNFi-refractory RA?
  • What are the prevailing areas of unmet need and opportunity in TNFi-refractory RA?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new drug targeting TNFi-refractory RA?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in February 2019

Key companies: Bristol-Myers Squibb, Roche, Pfizer, Eli Lilly, Incyte, Regeneron, Sanofi

Key drugs: Rituxan / MabThera, Orencia, Actemra / RoActemra, Xeljanz, Olumiant, Kevzara

Table of contents

  • Detailed, Expanded Analysis: TNF-alpha Refractory Rheumatoid Arthritis (US & EU )
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in TNFi-Refractory RA
      • Key Findings: Unmet Need in TNFi-Refractory RA and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the TNFi-Refractory Market and Emerging Therapy Insights
        • Opportunity: Therapies with Novel Mechanisms of Action
        • Opportunity: Therapies That Offer Improved Efficacy in Reducing Signs and Symptoms of the Disease and/or Achieving Clinical Remission
        • Opportunity: Oral Therapies with an Improved Safety Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • TNFi-Refractory RA Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Qinghui Yu, PhD
  • Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.

Purchase Report

Recent reports:
You may also be interested in: